May 21 (Reuters) - GSK plc:
* GSK PLC - POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB
* GSK: PRIMARY ENDPOINTS MET IN SWIFT-1 AND SWIFT-2 TRIALS Source text for Eikon: Further company coverage:
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,604 GBX | -0.34% | -1.50% | +10.64% |
Jun. 13 | REGENXBIO Inc. Announces Chief Executive Officer Changes | CI |
Jun. 12 | Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says | MT |
May 21 (Reuters) - GSK plc:
* GSK PLC - POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB
* GSK: PRIMARY ENDPOINTS MET IN SWIFT-1 AND SWIFT-2 TRIALS Source text for Eikon: Further company coverage:
1st Jan change | Capi. | |
---|---|---|
+10.64% | 83.76B | |
+50.50% | 795B | |
+41.96% | 627B | |
-7.27% | 350B | |
+18.41% | 328B | |
+8.90% | 294B | |
+18.02% | 245B | |
+1.27% | 222B | |
+11.95% | 215B | |
+3.50% | 160B |